PCRX (Pacira BioSciences) Net Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PCRX Pacira BioSciences Inc PCRX
69 GF Score
Price $24.43
GF Value $29.11
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Pacira BioSciences Net Loan?

Net Loan only applies to banks and insurance companies.

PCRX
69GF Score
Pacira BioSciences Inc PCRX
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Pacira BioSciences (PCRX) Overvalued in 2026?

Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued. The current stock price of $24.43 is trading 16.1% below its estimated GF Value™ of $29.11. GuruFocus considers Pacira BioSciences to be Modestly Undervalued.

Key valuation signals for PCRX:

  • Net Loan:
  • GF Value™: $29.11 vs. price of $24.43 (16.1% below fair value)
  • GF Score™: 69/100 with 7 warning signs

No single metric tells the full story. See the PCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pacira BioSciences Business Description

Other Exchanges 82P:Germany
Address 2000 Sierra Point Parkway, Suite 900, Brisbane, CA, USA, 94005
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
69GF Score

Get the complete analysis for PCRX

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.43
Price
$29.11
GF Value